Daratumumab - Induced Serologic Interference in Pre - Transfusion Testing: A Case Report
International Journal of Drug Delivery Technology · 03.07.2026 · 16 (61s)
DOI: 10.25258/ijddt.16.61s.46 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 03.07.2026. Verfasst von Anandan. S und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Pretransfusion testing is an essential prerequisite before releasing blood components for transfusion. Daratumumab, an anti-CD38 monoclonal antibody used in the treatment of Multiple Myeloma, is known to interfere with immunohematological testing by causing panagglutination in Antibody screening using 3 cell panel testing due to binding with CD38 expressed on reagent red blood cells. This interference may lead to positive antibody screening and incompatible crossmatches, thereby complicating timely transfusion support. Case Report: A 70-year-old male with Multiple Myeloma on daratumumab-based chemotherapy presented with symptomatic severe anemia (Hb 7.1 g/dL) associated with generalized weakness, exertional dyspnea, and dizziness. Pretransfusion testing revealed blood group A Rh-positive, weakly positive direct antiglobulin test (1+), auto-control of 0.5+, and panreactivity on antibody screening using 3 cell panel and further Antibody identification using 11 cell panel demonstrated panagglutination with weak to moderate against reagent red cells. Crossmatching with 13 donor packed red blood cell (PRBC) units demonstrated varying degrees of incompatibility, with one unit showing least incompatibility (0.5+). In view of urgent transfusion requirement and recent daratumumab administration, the serological findings were interpreted as daratumumab-associated interference. The least incompatible A Rh-positive PRBC unit was transfused safely under close monitoring without any adverse transfusion reaction. Post-transfusion hemoglobin improved from 7.1 g/dL to 8.1 g/dL with significant clinical improvement.
Discussion
Daratumumab-associated serologic interference represents a major challenge in transfusion medicine practice. Binding of the drug to CD38 on reagent red cells can result in persistent panreactivity in antibody screening, antibody identification, and antiglobulin crossmatching despite absence of clinically significant alloantibodies. Similar findings have been reported in previous studies, emphasizing the importance of awareness among clinicians and transfusion medicine specialists. Although mitigation strategies such as dithiothreitol-treated reagent cells and extended phenotyping are recommended, these techniques may not always be available in urgent settings. In such situations, transfusion of least incompatible blood after careful clinical and serologic correlation may be safely performed.
Conclusion
This case highlights the significant immunohematological challenges posed by daratumumab therapy during pretransfusion testing in patients with Multiple Myeloma. Recognition of characteristic serologic interference patterns, detailed drug history, and effective communication between clinicians and transfusion services are essential to avoid delays in transfusion support. In urgent clinical scenarios, transfusion of least incompatible PRBC units can be safely administered with appropriate monitoring when clinically significant alloantibodies are excluded.
Zitieren
APA
S, A., R, K., A, A., Rathan, N., & Kumar, S. (2026). Daratumumab - Induced Serologic Interference in Pre - Transfusion Testing: A Case Report. International Journal of Drug Delivery Technology, 16(61s). https://doi.org/10.25258/ijddt.16.61s.46
Vancouver
S A, R K, A A, Rathan N, Kumar S. Daratumumab - Induced Serologic Interference in Pre - Transfusion Testing: A Case Report. International Journal of Drug Delivery Technology. 2026;16(61s). doi:10.25258/ijddt.16.61s.46
BibTeX
@article{S2026,
author = {S, Anandan. and R, Krishnamoorthy and A, Ashwin and Rathan, Niranj and Kumar, Sampat},
title = {Daratumumab - Induced Serologic Interference in Pre - Transfusion Testing: A Case Report},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {61s},
doi = {10.25258/ijddt.16.61s.46}
}
EUVIMED